TG Therapeutics, Inc. (TGTX) stock
TGTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 9/303% above fair value
$62.71−0.05 (-0.08%)
Close on Nov 17, 2026Market cap $9.60BP/E 22.9Yield –
TG Therapeutics EV/EBITDA
EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.
TG Therapeutics's EV/EBITDA was 74.7× on Nov 11, 2026, against 50.9× a year earlier. Over the last 3 years it ranged from 34.4× to 167.3×, with a median of 60.7×.
EV/EBITDA at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 74.7× | +29.1 |
| 2025 | Dec 31, 2025 | 45.6× | +8.7 |
| 2024 | Oct 31, 2024 | 36.9× | – |
See a number that looks wrong?